Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Leukemia

Free Subscription Articles published in Eur J Haematol Retrieve available abstracts of 143 articles: HTML format

Single Articles

July 2021
1. GRIFFIN JD, Song Y, Yang H, Freimark J, et al
   Posttransplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: real-world treatment patterns and outcomes.
   Eur J Haematol. 2021 Jul 20. doi: 10.1111/ejh.13692.
   PubMed     Abstract available
   
   
   June 2021
2. PUNGOLINO E, D'adda M, De Canal G, Trojani A, et al
   Nilotinib induced Bone Marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: final report of the PhilosoPhi34 study.
   Eur J Haematol. 2021 Jun 17. doi: 10.1111/ejh.13680.
   PubMed     Abstract available
   
   
   May 2021
3. MACHHERNDL-SPANDL S, Jager E, Barna A, Gurbisz M, et al
   Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukemia.
   Eur J Haematol. 2021 May 16. doi: 10.1111/ejh.13647.
   PubMed     Abstract available
   
   
   
4. JONSDOTTIR G, Bjorkholm M, Turesson I, Hultcrantz M, et al
   Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.
   Eur J Haematol. 2021 May 9. doi: 10.1111/ejh.13650.
   PubMed     Abstract available
   
   
   April 2021
5. TEY A, Shaw B, Cardamone L, Shepherd S, et al
   Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome.
   Eur J Haematol. 2021 Apr 7. doi: 10.1111/ejh.13631.
   PubMed     Abstract available
   
   
   March 2021
6. BOUVIER A, Hamel JF, Delaunay J, Delabesse E, et al
   Molecular classification and prognosis in younger adults with acute myeloid leukemia patients and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: final results of the GOELAMS/FILO AML 2006-IR trial.
   Eur J Haematol. 2021 Mar 25. doi: 10.1111/ejh.13626.
   PubMed     Abstract available
   
   
   
7. DROZD-SOKOLOWSKA J, Karakulska-Prystupiuk E, Biecek P, Kobylinska K, et al
   Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis.
   Eur J Haematol. 2021 Mar 25. doi: 10.1111/ejh.13628.
   PubMed     Abstract available
   
   
   
8. JOUZIER C, Hamel JF, Dumas PY, Delaunay J, et al
   Conventional chemotherapy for Acute Myeloid Leukemia in older adults: impact on nutritional, cognitive and functional status.
   Eur J Haematol. 2021 Mar 18. doi: 10.1111/ejh.13624.
   PubMed     Abstract available
   
   
   
9. JEYAKUMAR N, Aldoss I, Yang D, Mokhtari S, et al
   Cytokine Gene Polymorphisms are Associated with Response to Blinatumomab in B Cell Acute Lymphoblastic Leukemia.
   Eur J Haematol. 2021 Mar 15. doi: 10.1111/ejh.13622.
   PubMed     Abstract available
   
   
   
10. KATSARAKI K, Adamopoulos PG, Papageorgiou SG, Pappa V, et al
    A 3' tRNA-derived fragment produced by tRNA(LeuAAG) and tRNA(LeuTAG) is associated with poor prognosis in B-cell chronic lymphocytic leukemia, independently of classical prognostic factors.
    Eur J Haematol. 2021 Mar 4. doi: 10.1111/ejh.13613.
    PubMed     Abstract available
    
    
    February 2021
11. CORTES JE, Kantarjian HM, Mauro MJ, An F, et al
    Long-Term Cardiac, Vascular, Hypertensive and Effusion Safety of Bosutinib in Patients With Philadelphia Chromosome-Positive Leukemia Resistant or Intolerant to Prior Therapy.
    Eur J Haematol. 2021 Feb 26. doi: 10.1111/ejh.13608.
    PubMed     Abstract available
    
    
    
12. SOLANA-ALTABELLA A, Boluda B, Rodriguez-Veiga R, Cano I, et al
    Healthcare Resource Utilization in Adult Patients with Relapsed/Refractory FLT3 mutated Acute Myeloid Leukemia: A Retrospective Chart Review from Spain.
    Eur J Haematol. 2021 Feb 20. doi: 10.1111/ejh.13604.
    PubMed     Abstract available
    
    
    January 2021
13. GEISSLER K, Jager E, Barna A, Graf T, et al
    Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival.
    Eur J Haematol. 2021 Jan 12. doi: 10.1111/ejh.13577.
    PubMed     Abstract available
    
    
    December 2020
14. MORABITO F, Tripepi G, Del Poeta G, Romana Mauro F, et al
    Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
    Eur J Haematol. 2020 Dec 30. doi: 10.1111/ejh.13573.
    PubMed     Abstract available
    
    
    
15. QUEUDEVILLE M, Schlegel P, Heinz AT, Lenz T, et al
    Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Eur J Haematol. 2020 Dec 15. doi: 10.1111/ejh.13569.
    PubMed     Abstract available
    
    
    
16. SEKINE M, Kameda T, Shide K, Maeda K, et al
    Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T-cell leukemia/lymphoma.
    Eur J Haematol. 2020 Dec 10. doi: 10.1111/ejh.13565.
    PubMed     Abstract available
    
    
    November 2020
17. STEINGRIMSSON V, Gislason GK, Thornorsteinsdottir S, Rognvaldsson S, et al
    A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era.
    Eur J Haematol. 2020 Nov 19. doi: 10.1111/ejh.13553.
    PubMed     Abstract available
    
    
    
18. KIMURA Y, Iwanaga E, Iwanaga K, Endo S, et al
    A regulatory element in the 3'-untranslated region of CEBPA is associated with myeloid/NK/T-cell leukemia.
    Eur J Haematol. 2020 Nov 16. doi: 10.1111/ejh.13551.
    PubMed     Abstract available
    
    
    
19. MOLICA S, Baumann T, Giannarelli D
    Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: results of a comparative performance analysis.
    Eur J Haematol. 2020 Nov 15. doi: 10.1111/ejh.13548.
    PubMed     Abstract available
    
    
    
20. MACHNICKI MM, Gorniak P, Pepek M, Szymczyk A, et al
    Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.
    Eur J Haematol. 2020 Nov 15. doi: 10.1111/ejh.13550.
    PubMed     Abstract available
    
    
    
21. CANAANI J, Danylesko I, Shemtov N, Zlotnick M, et al
    A phase II study of Bisantrene in patients with relapsed/refractory acute myeloid leukemia.
    Eur J Haematol. 2020 Nov 6. doi: 10.1111/ejh.13544.
    PubMed     Abstract available
    
    
    
22. SANCHEZ-PINA JM, Rodriguez Rodriguez M, Castro Quismondo N, Gil Manso R, et al
    Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies.
    Eur J Haematol. 2020;105:597-607.
    PubMed     Abstract available
    
    
    October 2020
23. UCHIDA Y, Yoshimitsu M, Hachiman M, Kusano S, et al
    RLTPR Q575E: A novel recurrent gain-of-function mutation in patients with adult T-cell leukemia/lymphoma.
    Eur J Haematol. 2020 Oct 24. doi: 10.1111/ejh.13540.
    PubMed     Abstract available
    
    
    
24. RAGHUNATHAN V, Fan G, Kittai AS, Okada C, et al
    A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.
    Eur J Haematol. 2020 Oct 22. doi: 10.1111/ejh.13538.
    PubMed     Abstract available
    
    
    
25. BELLMANN-WEILER R, Burkert F, Schwaiger T, Schmidt S, et al
    Janus-faced course of COVID-19 infection in patients with hematological malignancies.
    Eur J Haematol. 2020;105:502-504.
    PubMed    
    
    
    September 2020
26. ZUCENKA A, Pileckyte R, Trociukas I, Peceliunas V, et al
    Outcomes of Relapsed or Refractory Acute Myeloid Leukemia Patients Failing Venetoclax Based Salvage Therapies.
    Eur J Haematol. 2020 Sep 30. doi: 10.1111/ejh.13527.
    PubMed     Abstract available
    
    
    
27. OFRAN Y, Leiba R, Frisch A, Horesh N, et al
    Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.
    Eur J Haematol. 2020 Sep 18. doi: 10.1111/ejh.13518.
    PubMed     Abstract available
    
    
    
28. EGNELL C, Ranta S, Banerjee J, Merker A, et al
    Impact of body mass index on relapse in children with acute lymphoblastic leukemia treated according to Nordic treatment protocols.
    Eur J Haematol. 2020 Sep 10. doi: 10.1111/ejh.13517.
    PubMed     Abstract available
    
    
    
29. JOHANSSON P, Klein-Hitpass L, Roth A, Mollmann M, et al
    Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia.
    Eur J Haematol. 2020 Sep 2. doi: 10.1111/ejh.13511.
    PubMed     Abstract available
    
    
    
30. BAECKLUND F, Ekberg S, Rosenquist R, Askling J, et al
    Concordance in survival among first-degree relatives diagnosed with indolent lymphoid malignancies including chronic lymphocytic leukemia.
    Eur J Haematol. 2020 Sep 1. doi: 10.1111/ejh.13510.
    PubMed     Abstract available
    
    
    August 2020
31. ISHIKAWA C, Mori N
    The role of CUDC-907, a dual phosphoinositide-3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T-cell leukemia.
    Eur J Haematol. 2020 Aug 11. doi: 10.1111/ejh.13508.
    PubMed     Abstract available
    
    
    
32. ROBAK P, Jesionek-Kupnicka D, Kupnicki P, Polliack A, et al
    Bone lesions in hairy cell leukemia: Diagnosis and treatment.
    Eur J Haematol. 2020 Aug 5. doi: 10.1111/ejh.13505.
    PubMed     Abstract available
    
    
    
33. YOURON P, Singh C, Jindal N, Malhotra P, et al
    Quality of Life in patients of Chronic Lymphocytic Leukemia using the EORTC QLQ-C30 and QLQ-CLL17 Questionnaire.
    Eur J Haematol. 2020 Aug 3. doi: 10.1111/ejh.13503.
    PubMed     Abstract available
    
    
    
34. LAPPALAINEN M, Hamalainen S, Romppanen T, Pulkki K, et al
    Febrile neutropenia in patients with acute myeloid leukemia: outcome in relation to qSOFA score, C-reactive protein and blood culture findings.
    Eur J Haematol. 2020 Aug 2. doi: 10.1111/ejh.13500.
    PubMed     Abstract available
    
    
    July 2020
35. AARUP K, Rotbain EC, Enggaard L, Pedersen RS, et al
    Real-World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.
    Eur J Haematol. 2020 Jul 31. doi: 10.1111/ejh.13499.
    PubMed     Abstract available
    
    
    
36. KUZELOVA K, Obr A, Markova J, Gasova Z, et al
    Integrin expression and adhesivity to fibronectin in primary acute myeloid leukemia cells: impact of NPM1 and FLT3 mutations.
    Eur J Haematol. 2020 Jul 15. doi: 10.1111/ejh.13488.
    PubMed     Abstract available
    
    
    June 2020
37. LANGERBEINS P, Furstenau M, Gruell H, Klein F, et al
    COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemia.
    Eur J Haematol. 2020 Jun 23. doi: 10.1111/ejh.13475.
    PubMed     Abstract available
    
    
    
38. STEINGRIMSSON V, Gislason GK, Aspelund T, Turesson I, et al
    A population-based study on serious inpatient bacterial infections in patients with chronic lymphocytic leukemia and their impact on survival.
    Eur J Haematol. 2020 Jun 23. doi: 10.1111/ejh.13477.
    PubMed     Abstract available
    
    
    
39. ISHIKAWA C, Mori N
    MALT-1 as a novel therapeutic target for adult T-cell leukemia.
    Eur J Haematol. 2020 Jun 23. doi: 10.1111/ejh.13467.
    PubMed     Abstract available
    
    
    
40. SATAKE A, Konishi A, Azuma Y, Tsubokura Y, et al
    Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis.
    Eur J Haematol. 2020 Jun 21. doi: 10.1111/ejh.13474.
    PubMed     Abstract available
    
    
    
41. WU L, Xia M, Sun X, Han X, et al
    High levels of immunoglobulin expression predict shorter overall survival in patients with acute myeloid leukemia.
    Eur J Haematol. 2020 Jun 14. doi: 10.1111/ejh.13466.
    PubMed     Abstract available
    
    
    May 2020
42. BEZIAT G, Tavitian S, Bertoli S, Huguet F, et al
    Dactinomycin in acute myeloid leukemia with NPM1 mutations.
    Eur J Haematol. 2020 May 25. doi: 10.1111/ejh.13438.
    PubMed     Abstract available
    
    
    
43. CESINI L, Frieri C, Barate C, Sora F, et al
    Erythropoietin Treatment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Frontline Imatinib who Developed Late Anemia.
    Eur J Haematol. 2020 May 4. doi: 10.1111/ejh.13436.
    PubMed     Abstract available
    
    
    April 2020
44. CHOI Y, Lee JH, Lee JH, Park HS, et al
    Title: Monosomal karyotype affecting outcomes of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission.
    Eur J Haematol. 2020 Apr 30. doi: 10.1111/ejh.13434.
    PubMed     Abstract available
    
    
    
45. THIELEN FW, van Dongen-Leunis A, Arons A, Ladestein JR, et al
    Cost-Effectiveness of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-cell acute Lymphoblastic Leukemia.
    Eur J Haematol. 2020 Apr 14. doi: 10.1111/ejh.13427.
    PubMed     Abstract available
    
    
    
46. SITGES M, Boluda B, Garrido A, Morgades M, et al
    Scute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). study of 61 patients treated with intensive protocols.
    Eur J Haematol. 2020 Apr 3. doi: 10.1111/ejh.13417.
    PubMed     Abstract available
    
    
    
47. GOKBUGET N, Dombret H, Giebel S, Bruggemann M, et al
    Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.
    Eur J Haematol. 2020;104:299-309.
    PubMed     Abstract available
    
    
    March 2020
48. ZAJAC-SPYCHALA O, Irga-Jaworska N, Drozynska E, Muszynska-Roslan K, et al
    Mixed phenotype acute leukemia (MPAL): biological profile, clinical characteristic and treatment outcomes: report of the population-based study.
    Eur J Haematol. 2020 Mar 28. doi: 10.1111/ejh.13413.
    PubMed     Abstract available
    
    
    
49. MARCONI G, Talami A, Abbenante MC, Sartor C, et al
    Mec (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplantat in acute myeloid leukemia.
    Eur J Haematol. 2020 Mar 7. doi: 10.1111/ejh.13406.
    PubMed     Abstract available
    
    
    
50. LUCIANO L, Annunziata M, Attolico I, Di Raimondo F, et al
    The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: real-world data.
    Eur J Haematol. 2020 Mar 7. doi: 10.1111/ejh.13408.
    PubMed     Abstract available
    
    
    
51. VASUDEVAN NAMPOOTHIRI R, Law AD, Lam W, Chen C, et al
    Outcomes of Therapy Related Acute Lymphoblastic Leukemia in Adults after Allogeneic Stem Cell Transplantation.
    Eur J Haematol. 2020 Mar 1. doi: 10.1111/ejh.13403.
    PubMed     Abstract available
    
    
    February 2020
52. LENNMYR EB, Karlsson K, Abrahamsson M, Ebrahim F, et al
    Introducing Patient Reported Outcome in the Acute Leukemia Quality Registries in Sweden.
    Eur J Haematol. 2020 Feb 20. doi: 10.1111/ejh.13399.
    PubMed     Abstract available
    
    
    
53. LENARTOVA A, Johannesen TB, Tjonnfjord GE
    Chronic lymphocytic leukemia and secondary hematological malignancies: A nation-wide cancer registry study.
    Eur J Haematol. 2020 Feb 14. doi: 10.1111/ejh.13396.
    PubMed     Abstract available
    
    
    
54. MAYER K, Hahn-Ast C, Schwab K, Schmidt-Wolf IGH, et al
    Long-term follow-up of Cladribine, high-dose Cytarabine and Idarubicin as salvage treatment for Relapsed acute myeloid Leukemia and Literature Review.
    Eur J Haematol. 2020 Feb 12. doi: 10.1111/ejh.13395.
    PubMed     Abstract available
    
    
    
55. DILL V, Kauschinger J, Hauch RT, Buschhorn L, et al
    Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.
    Eur J Haematol. 2020;104:125-137.
    PubMed     Abstract available
    
    
    
56. CHOI JS, Berdis A
    An artificial nucleoside that simultaneously detects and combats drug resistance to doxorubicin.
    Eur J Haematol. 2020;104:97-109.
    PubMed     Abstract available
    
    
    January 2020
57. CALLEJA A, Yun S, Moreilhon C, Karsenti JM, et al
    Clonal selection in therapy related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
    Eur J Haematol. 2020 Jan 28. doi: 10.1111/ejh.13390.
    PubMed     Abstract available
    
    
    
58. STAUDER R, Lambert J, Desruol-Allardin S, Savre I, et al
    Patient-reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: literature review and landscape analysis.
    Eur J Haematol. 2020 Jan 27. doi: 10.1111/ejh.13389.
    PubMed     Abstract available
    
    
    December 2019
59. ORFALI N, O'Donovan TR, Cahill MR, Benjamin D, et al
    All-trans retinoic acid (ATRA) induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL).
    Eur J Haematol. 2019 Dec 6. doi: 10.1111/ejh.13367.
    PubMed     Abstract available
    
    
    November 2019
60. SOBAS M, Rodriguez-Veiga R, Vellenga E, Paluszewska M, et al
    Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols.
    Eur J Haematol. 2019 Nov 14. doi: 10.1111/ejh.13346.
    PubMed     Abstract available
    
    
    
61. PREM S, Atenafu EG, Avena J, Bautista R, et al
    Impact of central nervous system involvement in AML on outcomes after allotransplant and utility of pretransplant cerebrospinal fluid assessment.
    Eur J Haematol. 2019;103:483-490.
    PubMed     Abstract available
    
    
    September 2019
62. SENOUCI A, Smol T, Tricot S, Bakala J, et al
    Cytogenetic landscape in 1012 newly diagnosed chronic lymphocytic leukemia.
    Eur J Haematol. 2019 Sep 12. doi: 10.1111/ejh.13329.
    PubMed     Abstract available
    
    
    
63. KONUMA T, Kohara C, Watanabe E, Mizukami M, et al
    Circulating unconventional T cell subsets during treatment with BCR-ABL1 tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia.
    Eur J Haematol. 2019 Sep 11. doi: 10.1111/ejh.13328.
    PubMed     Abstract available
    
    
    
64. SANTALIESTRA M, Garrido A, Carricondo M, Bussaglia E, et al
    Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5-azacytidine: Identification of responding patients.
    Eur J Haematol. 2019;103:208-214.
    PubMed     Abstract available
    
    
    
65. LINDSTROM V, Hakkarainen KM, Mehtala J, Klement R, et al
    Observational evidence from patients diagnosed with chronic lymphocytic leukaemia (CLL) in Finland between 2005-2015 show improved survival over time.
    Eur J Haematol. 2019;103:190-199.
    PubMed     Abstract available
    
    
    
66. NAGAFUJI K, Miyamoto T, Eto T, Ogawa R, et al
    Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia.
    Eur J Haematol. 2019;103:164-171.
    PubMed     Abstract available
    
    
    August 2019
67. SALAS MQ, Prem S, Atenafu EG, Law AD, et al
    Reduced Intensity Allogeneic Stem Cell Transplant with Anti-Thymocyte globulin and Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia.
    Eur J Haematol. 2019 Aug 26. doi: 10.1111/ejh.13321.
    PubMed     Abstract available
    
    
    
68. LENNMYR E, Karlsson K, Ahlberg L, Garelius H, et al
    Survival in adult acute lymphoblastic leukaemia (ALL): A report from the Swedish ALL Registry.
    Eur J Haematol. 2019;103:88-98.
    PubMed     Abstract available
    
    
    July 2019
69. CHIU YC, Hsiao TH, Tsai JR, Wang LJ, et al
    Integrating resistance functions to predict response to induction chemotherapy in de novo acute myeloid leukemia.
    Eur J Haematol. 2019 Jul 29. doi: 10.1111/ejh.13301.
    PubMed     Abstract available
    
    
    
70. LAUSEKER M, Gerlach R, Worseg W, Haferlach T, et al
    Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: results from a population-based study.
    Eur J Haematol. 2019 Jul 15. doi: 10.1111/ejh.13293.
    PubMed     Abstract available
    
    
    
71. TADMOR T, Braester A, Najib D, Aviv A, et al
    A new risk model to predict time to first treatment in Chronic Lymphocytic Leukemia based on heavy chain immunoparesis and summated free light chain.
    Eur J Haematol. 2019 Jul 6. doi: 10.1111/ejh.13288.
    PubMed     Abstract available
    
    
    
72. KJAER L, Skov V, Andersen MT, Aggerholm A, et al
    Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.
    Eur J Haematol. 2019;103:26-34.
    PubMed     Abstract available
    
    
    June 2019
73. HUANG Y, Zou Y, Zheng R, Ma X, et al
    MiR-137 inhibits cell proliferation in acute lymphoblastic leukemia by targeting JARID1B.
    Eur J Haematol. 2019 Jun 17. doi: 10.1111/ejh.13276.
    PubMed     Abstract available
    
    
    May 2019
74. RAUTENBERG C, Kaivers J, Germing U, Haas R, et al
    Spontaneous remission in a patient with very late relapse of acute myeloid leukemia 17 years after allogeneic blood stem cell transplantation.
    Eur J Haematol. 2019 May 8. doi: 10.1111/ejh.13245.
    PubMed     Abstract available
    
    
    
75. HUEMER F, Melchardt T, Jansko B, Wahida A, et al
    Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.
    Eur J Haematol. 2019;102:437-441.
    PubMed     Abstract available
    
    
    April 2019
76. PASIC I, Da'na W, Lam W, Law A, et al
    Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML.
    Eur J Haematol. 2019;102:368-374.
    PubMed     Abstract available
    
    
    
77. CHELYSHEVA E, Turkina A
    Risks and challenges of CML management during pregnancy: Looking for a balanced decision.
    Eur J Haematol. 2019;102:378-379.
    PubMed    
    
    
    March 2019
78. NORGAARD JM, Friis LS, Kristensen JS, Severinsen MT, et al
    Addressing the Room for Improvement in Management of Acute Promyelocytic Leukemia.
    Eur J Haematol. 2019 Mar 19. doi: 10.1111/ejh.13229.
    PubMed     Abstract available
    
    
    
79. HAMMRICH J, Wittig S, Ernst T, Gruhn B, et al
    CTLA-4 polymorphism rs231775: Influence on relapse and survival after allogeneic hematopoietic stem cell transplantation in childhood.
    Eur J Haematol. 2019;102:251-255.
    PubMed     Abstract available
    
    
    
80. WARNY M, Helby J, Sengelov H, Nordestgaard BG, et al
    Bone marrow mononuclear cell telomere length in acute myeloid leukaemia and high-risk myelodysplastic syndrome.
    Eur J Haematol. 2019;102:218-226.
    PubMed     Abstract available
    
    
    February 2019
81. CAPODANNO I, Tamagnini E, Alfieri P, Codeluppi K, et al
    Home Care of Acute Leukemia Patients: from Active Therapy to End-of-Life and Palliative Care. The Three-year Experience of a Single Centre.
    Eur J Haematol. 2019 Feb 22. doi: 10.1111/ejh.13224.
    PubMed     Abstract available
    
    
    
82. ISHITSUKA K, Yurimoto S, Tsuji Y, Iwabuchi M, et al
    Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma.
    Eur J Haematol. 2019 Feb 10. doi: 10.1111/ejh.13220.
    PubMed     Abstract available
    
    
    
83. ABRUZZESE E, de Fabritiis P, Trawinska MM, Niscola P, et al
    Back to the future: Treatment-free remission and pregnancy in chronic myeloid leukemia.
    Eur J Haematol. 2019;102:197-199.
    PubMed    
    
    
    December 2018
84. GRIFFIN JD, Yang H, Song Y, Kinrich D, et al
    Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3-Mutated and Wild Type Acute Myeloid Leukemia: A Medical Chart Study.
    Eur J Haematol. 2018 Dec 22. doi: 10.1111/ejh.13205.
    PubMed     Abstract available
    
    
    
85. BALSAT M, Etienne M, Elhamri M, Hayette S, et al
    Successful pregnancies in patients with BCR-ABL-positive leukemias treated with interferon-alpha therapy during the tyrosine kinase inhibitors era.
    Eur J Haematol. 2018;101:774-780.
    PubMed     Abstract available
    
    
    
86. WEHMEYER J, Zaiss M, Losem C, Schmitz S, et al
    Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
    Eur J Haematol. 2018;101:766-773.
    PubMed     Abstract available
    
    
    November 2018
87. SAKAROU M, Eisele L, Duhrsen U, Huttmann A, et al
    Efficacy of the GMALL-B-ALL/NHL2002 Protocol in Burkitt Leukaemia/Lymphoma and Aggressive Non-Hodgkin-Lymphomas with or without CNS-Involvement.
    Eur J Haematol. 2018 Nov 24. doi: 10.1111/ejh.13199.
    PubMed     Abstract available
    
    
    October 2018
88. BERTOLI S, Paubelle E, Berard E, Saland E, et al
    Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels and their functional as well as prognostic roles in acute myeloid leukemia.
    Eur J Haematol. 2018 Oct 16. doi: 10.1111/ejh.13183.
    PubMed     Abstract available
    
    
    
89. AYPAR U, Smoley SA, Pitel BA, Pearce KE, et al
    Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia.
    Eur J Haematol. 2018 Oct 1. doi: 10.1111/ejh.13179.
    PubMed     Abstract available
    
    
    
90. ZAWITKOWSKA J, Lejman M, Zaucha-Prazmo A, Drabko K, et al
    Clinical characteristics and analysis of treatment result in children with Ph-positive acute lymphoblastic leukaemia in Poland between 2005 and 2017.
    Eur J Haematol. 2018;101:542-548.
    PubMed     Abstract available
    
    
    September 2018
91. BARBA P, Morgades M, Montesinos P, Gil C, et al
    Increased Survival due to Lower Toxicity for High Risk T-cell Acute Lymphoblastic Leukemia Patients in 2 consecutive Pediatric-Inspired PETHEMA Trials.
    Eur J Haematol. 2018 Sep 29. doi: 10.1111/ejh.13178.
    PubMed     Abstract available
    
    
    
92. KAYSER S, Levis MJ
    Clinical Implications of Molecular Markers in Acute Myeloid Leukemia.
    Eur J Haematol. 2018 Sep 10. doi: 10.1111/ejh.13172.
    PubMed     Abstract available
    
    
    
93. GAYOSO J, Balsalobre P, Kwon M, Herrera P, et al
    Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes.
    Eur J Haematol. 2018;101:332-339.
    PubMed     Abstract available
    
    
    
94. KRIEGSMANN K, Loffler H, Eckstein V, Schulz R, et al
    CD7 is expressed on a subset of normal CD34-positive myeloid precursors.
    Eur J Haematol. 2018;101:318-325.
    PubMed     Abstract available
    
    
    
95. WANG WJ, Zheng CF, Liu Z, Tan YH, et al
    Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression.
    Eur J Haematol. 2018;101:291-296.
    PubMed     Abstract available
    
    
    August 2018
96. CALITRI C, Ruberto E, Castagnola E
    Antibiotic prophylaxis in neutropenic children with acute leukemia: do the presently available data really support this practice?
    Eur J Haematol. 2018 Aug 14. doi: 10.1111/ejh.13162.
    PubMed     Abstract available
    
    
    
97. LAM TS, van de Meent M, Marijt EWA, Falkenburg JHF, et al
    Immune surveillance by autoreactive CD4 positive helper T-cells is a common phenomenon in patients with acute myeloid leukemia.
    Eur J Haematol. 2018 Aug 4. doi: 10.1111/ejh.13157.
    PubMed     Abstract available
    
    
    July 2018
98. HOEKS M, van der Pol M, Middelburg R, Evers D, et al
    Bone marrow iron score as an indicator for secondary iron overload in acute myeloid leukemia patients.
    Eur J Haematol. 2018 Jul 17. doi: 10.1111/ejh.13145.
    PubMed     Abstract available
    
    
    
99. BOUVIER A, Ribourtout B, Francois S, Orvain C, et al
    Donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation.
    Eur J Haematol. 2018 Jul 14. doi: 10.1111/ejh.13143.
    PubMed     Abstract available
    
    
    
100. ZACHARAKI D, Ghazanfari R, Li H, Lim HC, et al
     Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
     Eur J Haematol. 2018;101:57-67.
     PubMed     Abstract available
     
     
     
101. ARCIONI F, Roncadori A, Di Battista V, Tura S, et al
     Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
     Eur J Haematol. 2018;101:78-85.
     PubMed     Abstract available
     
     
     June 2018
102. JOFFE E, Goldschmidt N, Bairey O, Fineman R, et al
     Outcomes of Second-Line Treatment After Fludarabine Cyclophosphamide and Rituximab in Patients with Chronic Lymphocytic Leukemia Outside Clinical Trials.
     Eur J Haematol. 2018 Jun 27. doi: 10.1111/ejh.13129.
     PubMed     Abstract available
     
     
     
103. LATAGLIATA R, Breccia M, Carmosino I, Cesini L, et al
     Clinical Results According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: the Younger, the Later, the Worse?
     Eur J Haematol. 2018 Jun 13. doi: 10.1111/ejh.13110.
     PubMed     Abstract available
     
     
     
104. CLAERHOUT H, Van Aelst S, Melis C, Tousseyn T, et al
     Clinicopathological characteristics of de novo and secondary myeloid sarcoma: A monocentric retrospective study.
     Eur J Haematol. 2018;100:603-612.
     PubMed     Abstract available
     
     
     May 2018
105. BALL S, Vutthikraivit W, Maiti A, Short NJ, et al
     Infection with Ibrutinib in patients with Chronic Lymphocytic Leukemia (CLL): How strong is the association?
     Eur J Haematol. 2018 May 23. doi: 10.1111/ejh.13098.
     PubMed     Abstract available
     
     
     
106. REISER M, Dorfel S, Hensel M, Hoesl M, et al
     Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice.
     Eur J Haematol. 2018;100:455-464.
     PubMed     Abstract available
     
     
     
107. KURT H, Jorgensen JL, Amin HM, Patel KP, et al
     Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools.
     Eur J Haematol. 2018;100:444-454.
     PubMed     Abstract available
     
     
     April 2018
108. OTA S, Matsukawa T, Yamamoto S, Shinichi I, et al
     Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic phase chronic myeloid leukemia.
     Eur J Haematol. 2018 Apr 16. doi: 10.1111/ejh.13081.
     PubMed     Abstract available
     
     
     
109. TIEN FM, Hou HA, Tsai CH, Tang JL, et al
     Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients.
     Eur J Haematol. 2018 Apr 6. doi: 10.1111/ejh.13073.
     PubMed     Abstract available
     
     
     
110. GEELEN IGP, Thielen N, Janssen JJWM, Hoogendoorn M, et al
     Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe.
     Eur J Haematol. 2018;100:367-371.
     PubMed     Abstract available
     
     
     March 2018
111. PALMA M, Hansson L, Mulder TA, Adamson L, et al
     Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.
     Eur J Haematol. 2018 Mar 23. doi: 10.1111/ejh.13065.
     PubMed     Abstract available
     
     
     
112. ULLMARK T, Montano G, Gullberg U
     DNA and RNA binding by the Wilms' tumour gene 1 (WT1) protein +KTS and -KTS isoforms-From initial observations to recent global genomic analyses.
     Eur J Haematol. 2018;100:229-240.
     PubMed     Abstract available
     
     
     
113. ALJASEM HA, Messner HA, Lipton JH, Kim DDH, et al
     Outcome following second allogeneic hematopoietic cell transplantation: A single-center experience.
     Eur J Haematol. 2018;100:308-314.
     PubMed     Abstract available
     
     
     
114. CASADO LF, Hernandez JA, Jarque I, Echave M, et al
     Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia.
     Eur J Haematol. 2018;100:264-272.
     PubMed     Abstract available
     
     
     February 2018
115. ROBAK T, Blonski J, Skotnicki AB, Piotrowska M, et al
     Rituximab, cladribine and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial.
     Eur J Haematol. 2018 Feb 10. doi: 10.1111/ejh.13042.
     PubMed     Abstract available
     
     
     
116. KHALIL MMI, Lipton JH, Atenafu EG, Gupta V, et al
     Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.
     Eur J Haematol. 2018;100:198-205.
     PubMed     Abstract available
     
     
     January 2018
117. BURILLO-SANZ S, Morales-Camacho RM, Caballero-Velazquez T, Carrillo E, et al
     MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
     Eur J Haematol. 2018 Jan 31. doi: 10.1111/ejh.13037.
     PubMed     Abstract available
     
     
     
118. MURAI K, Yamaguchi K, Ito S, Miyagishima T, et al
     Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients.
     Eur J Haematol. 2018;100:27-35.
     PubMed     Abstract available
     
     
     December 2017
119. CUI W, Wang J, Nie RM, Zhao LL, et al
     Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
     Eur J Haematol. 2017 Dec 20. doi: 10.1111/ejh.13018.
     PubMed     Abstract available
     
     
     
120. JAMROZIAK K, Szymczyk A, Hus M, Wojciechowska M, et al
     Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report (PALG).
     Eur J Haematol. 2017 Dec 15. doi: 10.1111/ejh.13016.
     PubMed     Abstract available
     
     
     
121. GONG X, Lin D, Wang H, Wang Y, et al
     Flow Cytometric Analysis of Cerebrospinal Fluid in Adult Patients with Acute Lymphoblastic Leukemia during Follow-Up.
     Eur J Haematol. 2017 Dec 14. doi: 10.1111/ejh.13011.
     PubMed     Abstract available
     
     
     November 2017
122. SCHILLER J, Klein S, Engels M, Buttner R, et al
     A Cryptosporidium infection in a patient with relapsed T lymphoblastic lymphoma undergoing allogeneic stem cell transplantation.
     Eur J Haematol. 2017 Nov 15. doi: 10.1111/ejh.12998.
     PubMed     Abstract available
     
     
     
123. LENGFELDER E, Gorlich D, Nowak D, Spiekermann K, et al
     Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.
     Eur J Haematol. 2017 Nov 7. doi: 10.1111/ejh.12994.
     PubMed     Abstract available
     
     
     
124. COMBARIZA JF, Toro LF, Orozco JJ, Arango M, et al
     Cost-effectiveness analysis of interventions for prevention of invasive aspergillosis among leukemia patients during hospital construction activities.
     Eur J Haematol. 2017 Nov 6. doi: 10.1111/ejh.12991.
     PubMed     Abstract available
     
     
     October 2017
125. GONSALVES WI, Buadi FK, Kumar SK
     Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14).
     Eur J Haematol. 2017 Oct 24. doi: 10.1111/ejh.12986.
     PubMed     Abstract available
     
     
     
126. DUPLOYEZ N, Abou Chahla W, Lejeune S, Marceau-Renaut A, et al
     Detection of a new heterozygous germline ETV6 mutation in a case with hyperdiploid acute lymphoblastic leukemia (ALL).
     Eur J Haematol. 2017 Oct 16. doi: 10.1111/ejh.12981.
     PubMed     Abstract available
     
     
     
127. TULSTRUP M, Frandsen TL, Abrahamsson J, Lund B, et al
     Individualized 6-mercaptopurine increments in consolidation treatment of childhood acute lymphoblastic leukemia: a NOPHO randomized controlled trial.
     Eur J Haematol. 2017 Oct 6. doi: 10.1111/ejh.12979.
     PubMed     Abstract available
     
     
     September 2017
128. KAYSER S, Feszler M, Krzykalla J, Schick M, et al
     Clinical Impact of KMT2C and SPRY4 Expression Levels in Intensively Treated Younger Adult Acute Myeloid Leukemia Patients.
     Eur J Haematol. 2017 Sep 22. doi: 10.1111/ejh.12972.
     PubMed     Abstract available
     
     
     
129. SZARZYNSKA-ZAWADZKA B, Kosmalska M, Sedek L, Sonsala A, et al
     Cost-effective screening of DNMT3A coding sequence identifies somatic mutation in pediatric T-cell acute lymphoblastic leukemia.
     Eur J Haematol. 2017 Sep 14. doi: 10.1111/ejh.12964.
     PubMed     Abstract available
     
     
     August 2017
130. ISHIKAWA C, Senba M, Hashimoto T, Imaizumi A, et al
     Expression and significance of Pim-3 kinase in adult T-cell leukemia.
     Eur J Haematol. 2017 Aug 19. doi: 10.1111/ejh.12940.
     PubMed     Abstract available
     
     
     
131. PAPROCKA M, Bielawska-Pohl A, Rossowska J, Krawczenko A, et al
     MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients.
     Eur J Haematol. 2017 Aug 14. doi: 10.1111/ejh.12938.
     PubMed     Abstract available
     
     
     
132. WANG W, Bochtler T, Wuchter P, Manta L, et al
     Mesenchymal stromal cells contribute to quiescence of therapy resistant leukemic cells in acute myeloid leukemia.
     Eur J Haematol. 2017 Aug 11. doi: 10.1111/ejh.12934.
     PubMed     Abstract available
     
     
     July 2017
133. GEELEN IGP, Thielen N, Janssen JJWM, Levin MD, et al
     Influence of WHO versus ELN advanced phase chronic myeloid leukemia definitions on overall survival.
     Eur J Haematol. 2017 Jul 18. doi: 10.1111/ejh.12928.
     PubMed     Abstract available
     
     
     June 2017
134. D'ARENA G, Vitale C, Perbellini O, Coscia M, et al
     Prognostic relevance of oxidative stress measurement In chronic lymphocytic leukemia.
     Eur J Haematol. 2017 Jun 24. doi: 10.1111/ejh.12918.
     PubMed     Abstract available
     
     
     
135. NASILOWSKA-ADAMSKA B, Warzocha K, Solarska I, Borg K, et al
     BCRP mRNA and FLT3-ITD are independent poor risk factors in adult patients with acute myeloid leukemia and intermediate or normal karyotype.
     Eur J Haematol. 2017 Jun 15. doi: 10.1111/ejh.12913.
     PubMed     Abstract available
     
     
     
136. PELLO OM, Innes AJ, Bradshaw A, Finn SA, et al
     BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation.
     Eur J Haematol. 2017;98:632-634.
     PubMed     Abstract available
     
     
     May 2017
137. GLAVEY S, Quinn J, McCloy M, Sargent J, et al
     Emergence of Bruton's Tyrosine Kinase-negative Hodgkin Lymphoma During Ibrutinib Treatment of Chronic Lymphocytic Leukaemia.
     Eur J Haematol. 2017 May 31. doi: 10.1111/ejh.12911.
     PubMed     Abstract available
     
     
     
138. NAHI H, Genell A, Walinder G, Uttervall K, et al
     Incidence, characteristics and outcome of solitary plasmacytoma and plasma cell leukemia. Population based data from the Swedish Myeloma Register.
     Eur J Haematol. 2017 May 22. doi: 10.1111/ejh.12907.
     PubMed     Abstract available
     
     
     
139. KAWAMOTO K, Miyoshi H, Yanagida E, Yoshida N, et al
     Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
     Eur J Haematol. 2017;98:459-466.
     PubMed     Abstract available
     
     
     April 2017
140. KOZLOWSKI P, Lennmyr E, Ahlberg L, Bernell P, et al
     Age but not Philadelphia positivity impairs outcome in older/elderly patients with acute lymphoblastic leukemia in Sweden.
     Eur J Haematol. 2017 Apr 18. doi: 10.1111/ejh.12896.
     PubMed     Abstract available
     
     
     
141. LARFORS G, Sandin F, Richter J, Sjalander A, et al
     The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia.
     Eur J Haematol. 2017;98:398-406.
     PubMed     Abstract available
     
     
     
142. RAUTENBERG C, Nachtkamp K, Dienst A, Schmidt PV, et al
     Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.
     Eur J Haematol. 2017;98:348-354.
     PubMed     Abstract available
     
     
     March 2017
143. ZADA M, Lerner D, Piltz Y, Perry C, et al
     Familial Chronic Lymphocytic Leukemia in Israel: A Disproportionate Distribution Among Ashkenazi Jews.
     Eur J Haematol. 2017 Mar 31. doi: 10.1111/ejh.12889.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: